Skip to main content
editorial
. 2022 Jul 27;11(5):399–406. doi: 10.1159/000526163

Fig. 3.

Fig. 3

Treatment strategy for intermediate-stage HCC 2022. LEN+TACE is a treatment choice for TACE-suitable HCC with Child-Pugh A liver function. LEN followed by TACE is a treatment choice for TACE-unsuitable HCC with Child-Pugh A liver function. LEN-TACE is an optional treatment choice for curative TACE. ABC conversion treatment, including ABC (LEN)-TACE sandwich therapy, is an optional choice for treatment of patients with TACE-unsuitable HCC. These strategies can result in high complete response (CR) and deep partial response (PR), as well as durable, long-lasting cancer-free and drug-free status.